ArticleMolecular pharmacology2019
Probing the CB
Abstract read
In one paragraph
Article in Molecular pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.IBRO neuroscience reports · 2022Article
- Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.RSC medicinal chemistry · 2022Review
- Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Robert B LaprairieDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Kiran VemuriDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Edward L StahlDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Anisha KordeDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Jo-Hao HoDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Travis W GrimDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Tian HuaDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Yiran WuDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Raymond C StevensDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Zhi-Jie LiuDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Alexandros MakriyannisDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.).
Laura M BohnDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida (R.B.L., E.L.S., J.-H.H., T.W.G., L.M.B.); Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (K.V., A.K., A.M.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H., Y.W., Z.-J.L.); and Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California (R.C.S.) lbohn@scripps.edu.
Funding
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0MCannabinergic Medications for Methamphetamine AddictionR37DA023142 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2007 to 2016
$7.1MCIHRNIDA NIH HHS P01 DA009158NIDA NIH HHS R37 DA023142
Abstract
Cannabinoid receptor 1 (CB
Indexed as
AnimalsBinding SitesCannabinoid Receptor AntagonistsCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugHEK293 CellsHumansMaleMiceMice, Inbred C57BLNitratesPiperidinesProtein BindingProtein Structure, SecondaryAM6538Cannabinoid Receptor AntagonistsNitratesPiperidinesPyrazolesReceptor, Cannabinoid, CB1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.